Hyperkalemia News and Research

RSS
New polypill cheaper, better at reducing cardiovascular disease

New polypill cheaper, better at reducing cardiovascular disease

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

First-ever treatment for Merkel cell carcinoma receives approval in Japan

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Multifunctional scales can monitor health and inform about life threatening conditions

Multifunctional scales can monitor health and inform about life threatening conditions

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

MRA therapy does not improve outcome in heart attack patients without heart failure

MRA therapy does not improve outcome in heart attack patients without heart failure

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism